2015 American Transplant Congress
Kidney Vs. Heart Calculated PRA (CPRA) for Sensitized Heart Candidates: Does Donor Ethnic Distribution Make a Difference?
Background: CPRA, which is used for deceased donor (DD) kidney (KI) and pancreas/kidney-pancreas (PA/KP) allocation, is computed with KI DD HLA and ethnic frequencies. CPRA…2015 American Transplant Congress
Does the C1q Assay Predict the Result of Lymphocyte Flow Cross-Match (FCxM) in Potential Renal Transplant Recipients With HLA-DSA and AHG-CDC CxM negative?
Background. The presence of pre-transplant HLA donor specific antibodies (DSA) is a recognized risk factor for acute rejection. However, due to the test's (LUMINEX) high…2015 American Transplant Congress
Anti-Thymocyte Globulin Induction in Infected Mechanical Circulatory Support Patients: Is It Safe?
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The use of mechanical circulatory assist devices (MCSD) have been increasing over the past several years. Driveline infections (DLI) are one of the most…2015 American Transplant Congress
Impact of HLA Antibody Monitoring After Kidney Transplantation
The impact of donor specific antibodies (DSA) and optimal therapeutic intervention for DSA in kidney transplant (KT) recipients has been reported with variable results. We…2015 American Transplant Congress
Outcomes of Simultaneous Pancreas and Kidney Transplantation With a High Level of Preformed Antibodies
Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.
BACKGROUND:There is paucity of data of outcomes of simultaneous pancreas and kidney transplantation in recipients with preformed antibodies. Newer induction agents have been used with…2015 American Transplant Congress
Induction With an Interleukin-2 Receptor Antagonist in Sensitized Adult Kidney Transplant Recipients Is Highly Effective and Safe
Background: The effectiveness and safety of induction with basiliximab (IL2RA) in sensitized kidney transplant recipients is not clearly established. The aim of this study was…2015 American Transplant Congress
CTLA4Ig Administered During T-Cell Priming Negates de novo Alloantibody Responses and Modulates Recall Antibody Production
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Arcadia, CA.
Background CTLA4Ig (Belatacept) is a novel anti-rejection therapy aimed at costimulatory blockade. Clinical data suggest that post-transplant alloantibody formation is also reduced in patients treated…2015 American Transplant Congress
Molecular Features of Kidney Transplant Biopsies Without Allograft Injury in Relation With Type of Induction Therapy
Objective: Molecular evidence of allograft injury might precede histopathological findings of allograft injury. We aimed to investigate if the type of induction therapy effect intragraft…2015 American Transplant Congress
Characterization of Peripheral Blood T and B Cells of Sensitized Kidney Transplant Recipients With Long Term Stable Graft Function
We examined the phenotype of T and B cells of peripheral blood of sensitized kidney transplant recipients with stable graft function (GFR > 29mL/min) enrolled…2015 American Transplant Congress
Eculizumab as a Rescue Therapy for Rhinovirus-Induced Antibody Mediated Rejection After Incompatible Kidney Transplantation
Northwestern University, Chicago, IL.
Background: Despite being an effective strategy for overcoming ABO and HLA incompatibilities, desensitized kidney transplantation still has limitations. Early antibody mediated rejection (ABMR) may be…
American Transplant Congress abstracts